ESRX - Express Scripts Holding Company

YHD - YHD Delayed Price. Currency in USD
At close: 6:07PM EDT
Stock chart is not supported by your current browser
Previous CloseN/A
YTD ReturnN/A
Expense Ratio (net)N/A
CategoryN/A
Last Cap GainN/A
Morningstar RatingN/A
Morningstar Risk RatingN/A
Sustainability RatingN/A
Net AssetsN/A
Beta (3Y Monthly)N/A
YieldN/A
5y Average ReturnN/A
Holdings TurnoverN/A
Last DividendN/A
Average for CategoryN/A
Inception DateN/A
  • Moody's2 months ago

    Express Scripts Holding Company -- Moody's announces completion of a periodic review of ratings of Express Scripts Holding Company

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Express Scripts Holding Company and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers. This publication does not announce a credit rating action and is not an indication of whether or not a credit rating action is likely in the near future.

  • PR Newswire2 months ago

    Express Scripts Simplifies Digital Health Technology Marketplace for Consumers and Payers

    ST. LOUIS, May 16, 2019 /PRNewswire/ -- To make it simpler for consumers and payers to navigate the hundreds of thousands of currently available personal health technologies and interventions, Express Scripts, a Cigna company, will introduce the industry's first, stand-alone digital health formulary. "We are in an exciting age when technology is giving people even greater control of their own health and well-being. "We see a need to put mechanisms in place to help carefully manage these innovations, and are proud to lead again by being the first health services organization to establish a formulary of this nature.

  • Investing.com3 months ago

    Day Ahead: Top 3 Things to Watch

    Investing.com - Here’s a preview of the top 3 things that could rock markets tomorrow.

  • PR Newswire3 months ago

    Accredo, a Full-Service Specialty Pharmacy, Expands Best-in-Class Services with New Pharmacy in Hawaii

    ST. LOUIS, April 16, 2019 /PRNewswire/ -- Express Scripts today announced that its specialty pharmacy, Accredo, will open a new location in Honolulu to provide high-touch pharmacy care to people living with chronic, complex health conditions, such as multiple sclerosis, cancer and hemophilia. AlohaCare, a Hawaii-based, non-profit health plan, has selected Accredo as its preferred specialty pharmacy to serve its members living on Oahu, Kauai, Molokai, Lanai, Maui and Hawaii Island. "With its mission to care for people who are underserved with specific health needs, AlohaCare is a leader in putting patients first," said Brian Seiz, President, Accredo.

  • Investing.com4 months ago

    Cigna Shares Hit 52-Week Low on Trump Bid to Kill ACA

    Investing.com - The Trump Administration wants the entire Affordable Care Act (also known as Obamacare) declared unconstitutional and Cigna (NYSE:CI) shares fell back Tuesday as a result.

  • Moody's5 months ago

    Diplomat Pharmacy, Inc. -- Moody's downgrades Diplomat Pharmacy's CFR to B2; negative outlook

    Moody's Investors Service ("Moody's") downgraded the ratings of Diplomat Pharmacy, Inc. ("Diplomat") including the Corporate Family Rating to B2 from B1, the Probability of Default Rating to B2-PD from B1-PD, the senior secured rating to B2 from B1, and the Speculative Grade Liquidity Rating to SGL-3 from SGL-2. The downgrade of the Corporate Family Rating to B2 from B1 reflects challenging conditions in Diplomat's two major operating segments -- specialty pharmacy and pharmacy benefit management (PBM) -- that will keep debt/EBITDA elevated above the 4.5x threshold that Moody's incorporated in the prior rating of B1.

  • Richard Pzena Exits Express Scripts, Reduces Dover
    GuruFocus.com5 months ago

    Richard Pzena Exits Express Scripts, Reduces Dover

    Richard Pzena (Trades, Portfolio), t he founder and co-chief investment officer of Pzena Investment Management, sold shares of the following stocks during the fourth quarter. Warning! GuruFocus has detected 2 Warning Sign with QSR. The guru closed his Express Scripts Holding Co. (ESRX) stake.

  • Cigna Corp (CI) Q4 2018 Earnings Conference Call Transcript
    Motley Fool5 months ago

    Cigna Corp (CI) Q4 2018 Earnings Conference Call Transcript

    CI earnings call for the period ending December 31, 2018.

  • Reuters5 months ago

    Cigna CEO shrugs off concerns about proposed change to rebate rules

    The U.S. government's proposal to eliminate rebates that pharmacy benefit managers receive from drugmakers will not have a meaningful impact on growth, and does not affect the commercial market, Cigna Corp Chief Executive Officer David Cordani said on Friday. Investors are worried that Cigna, which closed its $52 billion acquisition of PBM Express Scripts in December, could be hurt by the Trump administration's proposal targeting after-market discounts that middlemen in the pharmaceutical supply chain have received for decades.

  • Anthem Stock Hits Buy Point Intraday On Strong Outlook, Earnings
    Investor's Business Daily6 months ago

    Anthem Stock Hits Buy Point Intraday On Strong Outlook, Earnings

    Anthem stock vaulted higher, touching a buy point intraday, after the company issued a far-better-than-expected profit forecast this year.

  • Moody's6 months ago

    Express Scripts Holding Company -- Moody's confirms Express Scripts at Baa2; stable outlook

    This concludes a rating review initiated on March 9, 2018 following the announcement that Cigna Corporation ("Cigna") reached a definitive agreement to acquire Express Scripts in a transaction valued at approximately $67 billion. Moody's changed the direction of the rating review from uncertain to downgrade on September 6, 2018.

  • Benzinga6 months ago

    Analysts: Cigna Offers Earnings Growth Potential, But Faces Legal Risks Tied To Aborted Anthem Deal

    Cigna Holding Co (NYSE: CI) recently completed its acquisition of pharmacy benefit manager Express Scripts. Raymond James analyst John Ransom upgraded Cigna from Market Perform to Outperform with a $215 price target. Wells Fargo Securities analyst Peter Costa maintained a Market Perform rating for Cigna and lowered the price target from $221 to $200.

  • GuruFocus.com6 months ago

    5 Health Care Stocks Gurus Are Buying

    Gilead on the list

  • 5 Great Healthcare Stocks to Buy for 2019
    Zacks7 months ago

    5 Great Healthcare Stocks to Buy for 2019

    Rapid innovation, major advances and an ageing population have managed to sustain the popularity of healthcare stocks.

  • 'Good for the region': Express Scripts CEO on what's next after the $54 billion Cigna buyout
    American City Business Journals7 months ago

    'Good for the region': Express Scripts CEO on what's next after the $54 billion Cigna buyout

    Express Scripts CEO Tim Wentworth on Thursday sought to calm fears that the company's $54 billion acquisition by insurer Cigna would negatively impact St. Louis.

  • Moody's7 months ago

    Connecticut General Life Insurance Company -- Moody's downgrades Cigna's long-term ratings (senior unsecured debt to Baa2); outlook stable

    Moody's Investors Service has downgraded Cigna Corporation's long-term ratings, including its senior unsecured debt rating to Baa2 from Baa1, upon the closing of its acquisition of Express Scripts Holding Company (ESI, Baa2, Review Down). Total senior unsecured debt of approximately $41 billion includes $20 billion issued by subsidiary Halfmoon Parent, Inc. (now known as Cigna Corporation), legacy Cigna Corporation (now known as Cigna Holding Company) debt of approximately $5.3 billion and legacy ESI debt of approximately $12.8 billion.

  • Reuters7 months ago

    Cigna closes $54 billion purchase of Express Scripts

    Cigna Corp (CI.N) on Thursday closed its $54-billion (42.65 billion pounds) deal to buy Express Scripts Holding Co, creating one of the biggest providers of pharmacy benefits and insurance plans in the United States, a combination it says will help it improve healthcare coordination and cut costs. Cigna's deal puts it in direct competition with two other healthcare companies set up the same way - Aetna with CVS Health Corp (CVS.N) and UnitedHealth Group Inc (UNH.N) with Optum. Cigna's deal has already passed antitrust scrutiny.

  • Express Scripts, Cigna finalize $54 billion merger
    American City Business Journals7 months ago

    Express Scripts, Cigna finalize $54 billion merger

    Cigna closed on its acquisition of north St. Louis County-based Express Scripts Thursday after receiving final regulatory approval for the $54 billion deal on Wednesday.

  • See what the IHS Markit Score report has to say about Express Scripts Holding Co.
    Markit7 months ago

    See what the IHS Markit Score report has to say about Express Scripts Holding Co.

    This could indicate that investors who seek to profit from falling equity prices are not currently targeting ESRX. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • PR Newswire7 months ago

    Celanese Set to Join S&P 500

    NEW YORK , Dec. 19, 2018 /PRNewswire/ -- Celanese Corp. (NYSE: CE) will replace Express Scripts Holding Co. (NASD: ESRX) in the S&P 500 effective prior to the open of trading on Monday, December 24 . S&P ...